Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14512274 | 1.00 | HDAC4 (0.53) | HDAC4HDAC2HDAC8USP2ALDH1A1 | |
| SCHEMBL12671605 | 1.00 | HDAC4 (0.53) | HDAC4HDAC2HDAC8USP2ALDH1A1 | |
| SCHEMBL20992899 | 1.00 | HDAC4 (0.53) | HDAC4HDAC2HDAC8USP2ALDH1A1 | |
| SCHEMBL23170502 | 0.85 | TRPA1 (0.42) | HDAC4HDAC2HDAC8AOC3HDAC7 | |
| SCHEMBL1006801 | 0.84 | HDAC4 (0.62) | HDAC4HDAC2HDAC8USP2ALDH1A1 | |
| SCHEMBL14607991 | 0.84 | AOC3 (0.41) | HDAC4HDAC2HDAC8AOC3HDAC7 | |
| SCHEMBL779646 | 0.84 | AOC3 (0.41) | HDAC4HDAC2HDAC8AOC3HDAC7 | |
| SCHEMBL12284676 | 0.82 | HDAC4 (0.44) | HDAC4AOC3HDAC7HDAC5IDO1 | |
| SCHEMBL12827072 | 0.82 | HDAC4 (0.44) | HDAC4AOC3HDAC7HDAC5IDO1 | |
| SCHEMBL31165000 | 0.82 | HDAC4 (0.44) | HDAC4AOC3HDAC7HDAC5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-04-28 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2103665-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-09-23 | — | — | EP | disclosed |
| US-20090118302-A1 | Novel Benzopyran Derivatives Having Inhibitory Activities Against Liver Fibrosis and Cirrhosis and Their Pharmaceutical Uses | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-05-07 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| EP-1032576-B1 | PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON ALPHA-AMMONIUM KETONES, IMINIUM KETONES OR AMIDINIUM KETONES AND ARYL BORATES | CIBA SC HOLDING AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | HDAC4 2407/4885HDAC2 1298/4885HDAC8 2241/4885 |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | HDAC4 3614/4885HDAC2 2252/4885HDAC8 3870/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | HDAC4 2514/4885HDAC2 2221/4885HDAC8 1896/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | HDAC4 796/4885HDAC2 583/4885HDAC8 867/4885 |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MT-ND2, MT-ND1, NLN | HDAC4 1063/4885HDAC2 829/4885HDAC8 1140/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | HDAC4 2576/4885HDAC2 3102/4885HDAC8 3235/4885 |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | HDAC4 1063/4885HDAC2 829/4885HDAC8 1140/4885 |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | HDAC4 2672/4885HDAC2 2646/4885HDAC8 2021/4885 |
| US-20090118302-A1 | Novel Benzopyran Derivatives Having Inhibitory Activities Against Liver Fibrosis and Cirrhosis and Their Pharmaceutical Uses | TGFBR1, TGFBR2, TGFB1 | HDAC4 1151/4885HDAC2 1902/4885HDAC8 606/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | HDAC4 3500/4885HDAC2 1412/4885HDAC8 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.